

VULVOVAGINAL CANDIDIASIS: A REAL-WORLD EVIDENCE STUDY OF THE PERCEIVED BENEFITS OF CANESTEN®

L. Zhang, R. De Salvo, A. Ehret, K. Young and S. Trapp



Objectives

Real-world evidence study, aimed to provide **consumer important information on the benefits of Canesten** (clotrimazole/fluconazole-based product) in the treatment of vulvovaginal candidiasis (VVC). The focus of the outcome is:

- > **Symptom Improvement and Relief.**
- > **Speed of Onset.**
- > **Quality of Life (QoL).**
- > **Product Attributes and Satisfaction.**

Study design



Retrospective observational study.



Web based interviews.

Population




Women who have used a Canesten product for **VVC within last 6 months**.

N=475. (UK=262 and Canada=213).



Age group



Results

45% Experienced **both internal and external symptoms**.



Of women stated that Canesten products **have improved their quality of life**.



Of women agree that Canesten products have **improved their symptoms**.



Of women who would **use Canesten again** if they had VVI.



Reported that Canesten products were **easy or very easy to use**.



Speed of Symptomatic Relief



Within **4 hours**.



Within **1 day**.



Agreed that the product start to **work from the first application**.



Of women that have tested both vaginal tablet alone and combi product (int + ext) claimed that **combi pack provides faster relief**.

Discussion

Canesten products not only **alleviate symptoms** effectively but also **enhance QoL**.

Canesten products provide **rapid onset of relief**, particularly with topical treatments.

Women experiencing both internal and external symptoms reported Canesten **combi pack (vaginal & external products)** to provide **faster relief of symptoms** than single product treatments.

Conclusion

The real-world evidence supports **Canesten's effectiveness** in providing **rapid relief from VVC symptoms**, significantly **improving QoL** and achieving **high consumer satisfaction**. Despite the study's limitations, we consider our findings to be robust and to add supplementary value to the information obtained from randomized trials of VVC therapies. These insights are crucial for guiding consumer choices regarding treatment options.